A new era in canine arthritis care: VMD approves Zoetis’ Lenivia for long-acting OA pain relief
The UK’s Veterinary Medicines Directorate (VMD) has approved Lenivia® (izenivetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in dogs. Granted on 29 May 2026, the approval makes Lenivia the first long-acting canine anti-nerve growth factor (NGF) monoclonal antibody therapy cleared for once-every-three-months administration. Backed by more than a decade of scientific research and development, Lenivia offers veterinary professionals and pet owners a new, convenient treatment option in a chronic condition that affects a substantial proportion of the UK dog population.
Understanding the Burden of Canine OA
Osteoarthritis is among the most prevalent chronic conditions in small animal practice, causing progressive joint breakdown, persistent pain, and reduced mobility. Unlike acute injuries, OA does not resolve on its own and because dogs are naturally stoic, the condition is frequently underrecognised and undertreated.
For owners, managing a dog with OA can be demanding. Many existing treatment options require daily oral medication, which can be difficult to maintain consistently. This compliance gap has long been a limiting factor in the effective management of canine OA pain.
How Lenivia Works
Lenivia targets NGF, a well-established mediator of pain and inflammation that is elevated in OA-affected joints. By binding to NGF and blocking its downstream effects, Lenivia addresses the pain pathway mechanistically rather than masking symptoms. While Zoetis’ existing product Librela® (bedinvetmab) uses the same anti-NGF approach, Lenivia binds to a different site on NGF, enabling its significantly extended duration of action.
Clinical Evidence and Practice Implications
In a nine-month field study, dogs receiving Lenivia showed increased mobility and reduced pain from the first injection. An important finding since early observable improvement supports owner engagement and treatment adherence over time. The therapy is intended as part of an individualised OA management plan under veterinary guidance.
For clinicians, the quarterly dosing schedule reduces the frequency of clinic visits and offers a practical option for patients who cannot tolerate NSAIDs, or where daily tablet administration is a challenge. Julia von Gablenz, Regional President for Europe and the Middle East at Zoetis, described the approval as “a meaningful milestone in our continued innovation for canine osteoarthritis pain.”
A Broader Shift in Veterinary Pain Management
The arrival of Lenivia in the UK market reflects a broader evolution in how the veterinary profession approaches chronic pain. The past several years has seen a shift away from purely symptomatic management towards therapies that address the underlying biology of pain.
Monoclonal antibody therapies, while still relatively new to veterinary practice, are becoming an increasingly important component of OA management protocols. Their targeted mechanism, injectable format, and – in the case of Lenivia – extended duration of action represents a meaningful step forward from traditional pharmacological approaches.
For the dogs who live with OA, and for the owners and veterinary teams who support them, Lenivia’s UK approval represents a practical and scientifically grounded addition to the management landscape.
